Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29319871 | 0.90 | LMNA (0.35) | CHRM2CHRM1CHRM3LMNAKDM1A | |
| SCHEMBL29319667 | 0.90 | KDM1A (0.37) | LMNAKDM1AMAOB | |
| SCHEMBL29319886 | 0.90 | EPHX2 (0.35) | CHRM2CHRM1CHRM3KDM1AMAOB | |
| SCHEMBL29319888 | 0.89 | CHRM2 (0.34) | CHRM2CHRM1CHRM3LMNAKDM1A | |
| SCHEMBL29319880 | 0.87 | CHRM2 (0.34) | CHRM2CHRM1CHRM3LMNAKDM1A | |
| SCHEMBL29338306 | 0.87 | CHRM2 (0.35) | CHRM2CHRM1CHRM3LMNAKDM1A | |
| SCHEMBL24138736 | 0.87 | CHRM2 (0.36) | CHRM2CHRM1CHRM3LMNAKDM1A | |
| SCHEMBL29319895 | 0.85 | CHRM2 (0.34) | CHRM2CHRM1CHRM3LMNAKDM1A | |
| SCHEMBL29338307 | 0.85 | CHRM2 (0.34) | CHRM2CHRM1CHRM3LMNAKDM1A | |
| SCHEMBL29338354 | 0.85 | CHRM2 (0.35) | CHRM2CHRM1CHRM3LMNAKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | IFNAR1, NR4A3, NR0B2 | CHRM2 2158/4885CHRM1 2064/4885CHRM3 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.